<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346330</url>
  </required_header>
  <id_info>
    <org_study_id>750P1C01</org_study_id>
    <nct_id>NCT03346330</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750</brief_title>
  <official_title>An Exploratory, Randomised, Double-blind, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food-effect of TRK-750 in Healthy Adults and Patients With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Toray Industries, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, randomised, double-blind, placebo-controlled, Phase I study to assess
      the safety, tolerability, pharmacokinetics, pharmacodynamics and food-effect of single and
      multiple, ascending oral doses of TRK-750 in healthy adults and patients with peripheral
      neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in laboratory safety tests</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with morphological and/or rhythm abnormalities on electrocardiogram</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in electrocardiogram time intervals</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:systolic blood pressure(mmHg)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:diastolic blood pressure(mmHg)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:pulse rate(bpm)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:body temperature(Â°C)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Healthy, Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>TRK-750, single and multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, single and multiple doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRK-750</intervention_name>
    <description>TRK-750 capsule</description>
    <arm_group_label>TRK-750, single and multiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo, single and multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers

          -  Female subjects who are either:

               1. Non-childbearing potential, or permanently sterile OR

               2. Childbearing potential and agree to use at least one form of highly effective
                  contraception

          -  Male subjects, with a female sexual partner of childbearing potential or a pregnant or
             breastfeeding partner, must agree to use barrier contraception (male condom) for the
             treatment period and for at least three months after the end of the systemic exposure
             of the study drug.

          -  Satisfactory medical assessment with no clinically significant or relevant
             abnormalities.

          -  Ability to provide written, personally signed, and dated informed consent.

        Exclusion Criteria:

          -  Current or recurrent disease

          -  Current or relevant history of physical or psychiatric illness

          -  Positive test for Hepatitis B, Hepatitis C or human immunodeficiency virus antibody
             (HIV) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TRK-750 Team</last_name>
    <phone>+49(0)6102/7999 0</phone>
    <email>medical@toray-intl.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

